MXCT vs PFE · rev $38.6M vs P/E 20, rev $62.58B
MaxCyte Inc (MXCT) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
MXCT currently screens at market cap $124.3M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the MXCT and PFE stock pages for the full models.
Not investment advice.